Sanorin spray 0.1%, 10ml

• Acute rhinitis of various etiologies;

• otitis media - as an additional agent to reduce swelling of the nasopharyngeal mucosa;

• sinusitis;

• eustachitis;

• laryngitis;

• to reduce swelling of the mucous membranes of the nasal cavity, nasopharynx and paranasal sinuses during diagnostic and therapeutic procedures;

• if necessary, stop nosebleeds.

Applied intranasally. 1-3 doses of the drug are injected into each nasal passage 3-4 times / day.

Duration of use - no more than 1 week in adults and no more than 3 days in children. If nasal breathing is facilitated, then the use of the drug Sanorin can be finished earlier. Re-use of the drug is possible after a few days.

When using the spray for the first time, it is recommended to press the dispenser several times until a compact aerosol cloud appears.

Before direct use, remove the protective cap, hold the bottle in an upright position, insert the end of the dispensing device into the nasal passage, then quickly and sharply press the applicator. It is recommended to inhale slightly through the nose immediately after injection.

After using the drug, close the applicator with a protective cap.

Nasal spray 0.1% in the form of a clear, colorless liquid, no visible particles, odorless.

1 ml 1 fl.

naphazoline nitrate 1 mg 10 mg

Excipients: ethylenediamine qs (about 400 ?g), boric acid - 170 mg, methyl parahydroxybenzoate - 10 mg, water - up to 10 ml.

• Chronic rhinitis;

• atrophic rhinitis;

• angle-closure glaucoma;

• severe eye diseases;

• arterial hypertension;

• severe atherosclerosis;

• tachycardia;

• hyperthyroidism;

• diabetes;

• simultaneous administration of MAO inhibitors and a period up to 14 days after the end of their use;

• children and adolescents up to 15 years old;

• hypersensitivity to the components of the drug.

• The drug should be used with caution during pregnancy, lactation (breastfeeding), with ischemic heart disease (angina pectoris), prostatic hyperplasia, pheochromocytoma.

pharmachologic effect

Alpha2-adrenergic agonist with a direct stimulating effect on ?-adrenergic receptors of the sympathetic nervous system. When administered intranasally, it has a quick, pronounced and prolonged vasoconstrictor effect on the vessels of the mucous membrane of the nasal cavity, nasopharynx and paranasal sinuses - it reduces swelling and hyperemia, thereby improving the patency of the nasal passages and facilitating nasal breathing. Along with this, the patency of the Eustachian tubes is restored.

The therapeutic effect occurs, as a rule, within 5 minutes after the administration of the drug and lasts for 4-6 hours. With prolonged use, the vasoconstrictor effect gradually decreases, therefore, after 5-7 days of treatment, you should take a break for several days.

Side effect

Local reactions: with increased sensitivity, a burning sensation and dryness in the nasal cavity is possible; in rare cases, after cessation of exposure - reactive hyperemia and edema of the nasal mucosa. With prolonged and frequent use (more than 1 week) of the drug Sanorin, chronic obstruction of the nasal passages and atrophy of the nasal mucosa are possible.

From the digestive system: very rarely - nausea.

From the side of the cardiovascular system: very rarely - tachycardia, increased blood pressure.

From the side of the central nervous system: very rarely - headache, irritability.

Others: very rarely - excessive sweating, allergic reactions, rash.

At the recommended doses, the drug is usually well tolerated.

Application during pregnancy and lactation

If it is necessary to use the drug during pregnancy and lactation (breastfeeding), the expected benefits of therapy for the mother and the possible risk to the fetus should be assessed.

There is no data on the penetration of naphazoline through the placental barrier, as well as into breast milk.

Application in children

Contraindicated in children and adolescents under 15 years of age.

special instructions

Caution is required when conducting general anesthesia with the use of anesthetics that increase the sensitivity of the myocardium to sympathomimetics (halothane), especially in patients with bronchial asthma.

Long-term use of the drug should be avoided.

In view of the possible development of side effects from the cardiovascular system and the nervous system, the recommended dose of the drug should not be exceeded.

Influence on the ability to drive vehicles and mechanisms

The drug does not affect the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions, taking into account the profile of side effects.

Overdose

Symptoms: nervousness, excessive sweating, headache, tremors, tachycardia, palpitations, increased blood pressure, nausea, cyanosis, respiratory and mental disorders are also possible. In the case of depression of the central nervous system, bradycardia, weakness, drowsiness, a decrease in body temperature, increased sweating, collapse, and, extremely rarely, coma are observed.

Treatment: drug withdrawal, symptomatic therapy.

Drug interactions

With the simultaneous use of the drug with MAO inhibitors or tricyclic antidepressants (and within 14 days after the end of their use), an increase in blood pressure is possible, which is due to the release of deposited catecholamines under the action of naphazoline. Therefore, the use of the drug Sanorin is contraindicated simultaneously with MAO inhibitors and within 14 days after their cancellation.

Naphazoline slows down the absorption of local anesthetics, which leads to an increase in the duration of their action.